这项发现为我们提供了一个全新的视角来评估免疫治疗的长期效果。通过检测患者肿瘤组织中前体耗竭性T细胞（Texp）的比例，我们或许能够更准确地预测他们未来复发的风险，从而为制定更个体化的治疗和随访策略提供依据。

For the 80 million people worldwide with celiac disease, the only treatment available is to cut grains like pasta and bread out of their lives. | For the 80 million people worldwide who have celiac ...

A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...

FibroGen (FGEN) announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46, an Immune-Modulating Antibody-Drug ...

A new anti-HER2 IgE antibody potentially offers new therapy options for treatment-resistant breast and ovarian cancers.

Aura Biosciences (AURA) announced data from a completed Phase 1 window of opportunity trial of bel-sar in patients with NMIBC. These data were ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...